Eczema (atopic dermatitis) guide: the barrier, the immune dysregulation, and the evidence-based treatment ladder

Atopic dermatitis (eczema) is the most common inflammatory skin disease — affecting approximately 20% of children and 3–10% of adults globally. It is not simply dry skin or an allergy: it is a complex disease driven by an inherited barrier defect and an immune dysregulation that perpetuate each other in a self-reinforcing cycle. Understanding this cycle is key to understanding why treatment requires addressing both the barrier and the inflammation simultaneously. Here is the complete evidence-based guide.

The pathophysiology: the barrier–immune cycle

The filaggrin mutation

The most important genetic discovery in atopic dermatitis was the identification of loss-of-function mutations in the filaggrin gene (FLG) by McLean et al. and Palmer et al. in 2006 (Nature Genetics). These mutations are present in approximately 30% of AD patients in Northern European populations.

Filaggrin's role: Filaggrin (filament-aggregating protein) is expressed in the granular layer of the epidermis during terminal differentiation of keratinocytes. It:

Aggregates keratin filaments → forms the compact protein matrix of the corneocyte
Is proteolytically broken down into natural moisturizing factor (NMF) components — urocanic acid, pyrrolidone carboxylic acid, amino acids — that maintain stratum corneum hydration and the slightly acidic skin pH (pH 4.5–5.5)

Consequences of FLG mutation:

Reduced corneocyte structural integrity
Depleted NMF → reduced stratum corneum hydration
Elevated skin pH (less acidic) → impaired activity of acid-dependent antimicrobial peptides → dysbiosis with Staphylococcus aureus overgrowth
Disrupted tight junctions between keratinocytes → increased permeability to allergens, irritants, and microbes

The Th2 immune dysregulation

The permeable barrier allows allergen penetration → dendritic cells in the epidermis capture and present allergens → drives differentiation of naïve T cells toward a Th2 dominant immune response → production of:

IL-4 and IL-13: The central AD cytokines — they suppress ceramide synthesis (compounding the barrier defect), increase IgE production (driving sensitization), and directly promote itch signaling
IL-31: The primary pruritogen in AD — directly activates itch-mediating sensory neurons; levels correlate with itch intensity
TSLP (thymic stromal lymphopoietin): Released by stressed keratinocytes → amplifies the Th2 response

The itch-scratch cycle

IL-31 and TSLP activate itch-sensing neurons (primarily TRPA1 and TRPV1 channels) → pruritus → scratching → physical barrier disruption → further allergen penetration → amplified immune response → more itch. This cycle drives disease chronicity.

S. aureus role: Staphylococcus aureus colonizes AD skin at much higher rates than normal skin — affecting >90% of AD lesional skin. S. aureus:

Produces toxins that act as superantigens → non-specifically activate T cells → amplify inflammation
Produces proteases that degrade filaggrin and tight junctions → worsen the barrier
Disrupts the skin microbiome by suppressing S. epidermidis (which produces antimicrobial peptides and competes with S. aureus)

Diagnosis: what atopic dermatitis looks like

Classic presentation by age:

Infants (0–2 years): Erythematous papules and vesicles on cheeks, scalp, and extensor surfaces (arms, legs); weeping and crusted lesions; intense pruritus evidenced by rubbing

Children (2–12 years): Flexural distribution — antecubital fossae (inner elbows), popliteal fossae (behind knees), wrists, ankles; lichenification (skin thickening from chronic rubbing); excoriations

Adolescents/adults: Flexural predilection persists; hand and eyelid eczema common; may present as nummular (coin-shaped) plaques or generalized dry, itchy skin without classic lichenification

Hanifin & Rajka criteria (1980): The historical diagnostic standard — major criteria (pruritus, flexural distribution, chronic relapsing course, atopic personal/family history) plus minor criteria (early age of onset, elevated IgE, Dennie-Morgan lines, etc.)

The treatment ladder

Step 1: Barrier repair (all patients, always)

Emollient use is the foundation of AD treatment — not a "nice-to-have" but a cornerstone that reduces flare frequency, reduces topical corticosteroid requirements, and improves quality of life.

Soak-and-seal protocol: The most evidence-supported emollient application method:

Bathe in warm (not hot) water for 5–10 minutes
Pat skin dry gently, leaving slightly damp
Apply emollient within 3 minutes of bathing to seal in moisture

Emollient selection: Ceramide-containing formulations outperform basic petrolatum or simple moisturizers for AD specifically (evidence reviewed in the ceramide guide). The three-lipid formulation (ceramides + cholesterol + fatty acids) at approximately 1:1:1 molar ratio restores the lamellar bilayer most effectively.

Frequency: Emollients should be applied at least twice daily to all affected areas and once daily to the full body — not just during flares.

Step 2: Topical corticosteroids (TCS) — acute flares

Topical corticosteroids remain the first-line anti-inflammatory treatment for acute AD flares.

Potency classes:

Class 1 (superpotent): Clobetasol propionate 0.05% — reserve for thick lichenified plaques on adults; avoid face and flexures
Class 2–3 (mid-potency): Triamcinolone acetonide 0.1%, mometasone furoate 0.1% — workhorse for moderate AD on body
Class 6–7 (low-potency): Hydrocortisone 1–2.5% — face, eyelids, skin folds, infants; prolonged use safety

Proactive "weekend therapy": For patients with frequent flares in the same locations, applying a mid-potency TCS twice weekly to habitually affected sites (even when clear) reduces relapse frequency — demonstrated in RCTs for mometasone and fluticasone.

Side effects: Skin atrophy, telangiectasia, striae with prolonged high-potency use; HPA-axis suppression with very large surface area application of potent TCS.

Step 3: Topical calcineurin inhibitors (TCIs)

Tacrolimus (Protopic) and pimecrolimus (Elidel): Non-steroidal anti-inflammatory topicals — inhibit calcineurin → block NFAT transcription factor → reduce IL-2, IL-4, IL-13, and other cytokine production in T cells.

Advantages over TCS: No skin atrophy risk → appropriate for long-term use, face, and sensitive areas. Approved for second-line therapy and steroid-sparing use.

Disadvantages: Initial stinging on application (especially tacrolimus); FDA black box warning regarding theoretical lymphoma risk (based on calcineurin inhibitor immunosuppression in organ transplant patients — no causal link established for topical use at cosmetic concentrations; considered a precautionary label by most dermatologists).

Step 4: Topical PDE4 inhibitors

Crisaborole (Eucrisa) 2%: A non-steroidal phosphodiesterase-4 (PDE4) inhibitor — PDE4 degrades cyclic AMP; inhibiting PDE4 raises cAMP → reduces inflammatory cytokine production. FDA-approved for mild-to-moderate AD in patients ≥3 months.

Roflumilast (Zoryve) 0.15%: Newer PDE4 inhibitor; FDA-approved for AD in patients ≥6 years.

Step 5: Biologics — dupilumab

Dupilumab (Dupixent): Anti-IL-4Rα monoclonal antibody — blocks the shared receptor for IL-4 and IL-13 simultaneously → the single most effective intervention for the central Th2 cytokine pathway driving AD.

Evidence: Multiple pivotal RCTs (LIBERTY AD SOLO-1 and SOLO-2, Blauvelt et al. 2017, Lancet) — dupilumab 300 mg every 2 weeks produced 36–38% EASI-75 response (75% reduction in Eczema Area and Severity Index) vs. 8–10% placebo. Dramatic improvement in pruritus, sleep, and quality of life. FDA-approved 2017 for moderate-to-severe AD adults; subsequently approved for adolescents, children, and infants.

IL-31 and TSLP biologics: Nemolizumab (anti-IL-31Rα) targets the primary pruritogen — phase 3 trials show significant itch reduction. Tezepelumab (anti-TSLP) in trials for AD. These represent next-generation targeted options.

Step 6: JAK inhibitors

Oral: Upadacitinib (Rinvoq), abrocitinib (Cibinqo) — JAK1 selective inhibitors; FDA-approved for moderate-to-severe AD. In head-to-head trials, upadacitinib showed superiority to dupilumab on some endpoints (faster itch relief, higher EASI-90 response rates). Risk profile includes increased infection susceptibility; MACE risk (class effect of JAK inhibitors); avoid in patients with cardiovascular risk factors.

Topical: Ruxolitinib (Opzelura) 1.5% cream — JAK1/2 inhibitor; FDA-approved for mild-to-moderate AD ≥12 years; minimal systemic absorption at labeled dose.

Trigger identification and avoidance

Individual triggers vary but commonly include:

Irritants: Harsh soaps (SLS), fragranced products, wool, synthetic fabrics, wet work
Allergens: House dust mite, pet dander, mold spores (aeroallergens); food allergens (cow's milk, egg, peanut, wheat, soy in infants/young children)
Climate: Low humidity (winter, air-conditioned environments); excessive heat and sweating
Stress: Psychosocial stress triggers AD flares via neuropeptide-mediated skin inflammation
S. aureus colonization: Treating recurrent S. aureus overgrowth (dilute bleach baths — 0.005% sodium hypochlorite, i.e., ½ cup household bleach in full tub, twice weekly) reduces flare frequency

Bleach bath evidence: Huang et al. (2009, Pediatrics): RCT demonstrating dilute bleach baths + intranasal mupirocin in pediatric AD — significant reduction in disease severity scores and S. aureus colonization. A low-cost, evidence-based adjunct.

Looking for a skincare or dermatology consultation? Browse med spa providers on MedSpot →